Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review

被引:9
作者
Gatteschi, Lavinia [1 ]
Iannopollo, Mauro [2 ]
Gonfiotti, Alessandro [1 ]
机构
[1] Univ Florence, Cardiothorac Dept, Thorac Surg Unit, I-50100 Florence, Italy
[2] Cent Tuscany AUSL, San Jacopo Hosp, Oncol Dept, Oncol Unit, I-51100 Pistoia, Italy
来源
LIFE-BASEL | 2021年 / 11卷 / 10期
关键词
resectable NSCLC; neoadjuvant immunotherapy; immune checkpoint inhibitors; SINGLE-ARM; OPEN-LABEL; CHEMOTHERAPY; ATEZOLIZUMAB; MULTICENTER; NIVOLUMAB;
D O I
10.3390/life11101036
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Lung cancer is one of the most common malignant tumors and it is the leading cause of cancer-related mortality worldwide. For early-stage Non-Small Cell Lung Cancer (NSCLC), surgical resection is the treatment of choice, but the 5-year survival is still unsatisfying, ranging from 60% to 36% depending on the disease stage. Multimodality treatment with adjuvant chemotherapy did not lead to clinically relevant results, improving survival rates by only 5%. Recently, immune checkpoint inhibitors (ICIs) are being studied as neoadjuvant treatment for resectable NSCLC too, after the satisfactory results obtained in stage IV disease. Several clinical trials are evaluating the safety and feasibility of neoadjuvant immunotherapy and their early findings suggest that ICIs could be better tolerated than standard neoadjuvant chemotherapy and more effective in reducing cancer local recurrence and metastasis. The aim of this review is to retrace the most relevant results of the completed and the ongoing clinical trials, in terms of efficacy and safety, but also to face the open challenges regarding ICIs in neoadjuvant setting for resectable NSCLC.</p>
引用
收藏
页数:8
相关论文
共 35 条
[1]   Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].
Albain, Kathy S. ;
Swann, R. Suzanne ;
Rusch, Valerie W. ;
Turrisi, Andrew T., III ;
Shepherd, Frances A. ;
Smith, Colum ;
Chen, Yuhchyau ;
Livingston, Robert B. ;
Feins, Richard H. ;
Gandara, David R. ;
Fry, Willard A. ;
Darling, Gail ;
Johnson, David H. ;
Green, Mark R. ;
Miller, Robert C. ;
Ley, Joanne ;
Sause, Willliam T. ;
Cox, James D. .
LANCET, 2009, 374 (9687) :379-386
[2]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[3]   Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial [J].
Besse, B. ;
Adam, J. ;
Cozic, N. ;
Chaput-Gras, N. ;
Planchard, D. ;
Mezquita, L. ;
Remon Masip, J. ;
Lavaud, P. ;
Naltet, C. ;
Gazzah, A. ;
de Montpreville, V. Thomas ;
Ghigna, M. -R. ;
Mussot, S. ;
Fadel, E. ;
Mabille, L. ;
Duchemann, B. ;
Barlesi, F. ;
Soria, J-C. ;
Caramella, C. ;
Mercier, O. .
ANNALS OF ONCOLOGY, 2020, 31 :S794-S795
[4]   Timing of Local and Distant Failure in Resected Lung Cancer Implications for Reported Rates of Local Failure [J].
Boyd, Jessamy A. ;
Hubbs, Jessica L. ;
Kim, Dong W. ;
Hollis, Donna ;
Marks, Lawrence B. ;
Kelsey, Chris R. .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) :211-214
[5]   Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data [J].
Burdett, Sarah ;
Rydzewska, Larysa H. M. ;
Tierney, Jayne F. ;
Auperin, Anne ;
Le Pechoux, Cecile ;
Le Chevalier, Thierry ;
Pignon, Jean-Pierre .
LANCET, 2014, 383 (9928) :1561-1571
[6]   Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial [J].
Carthon, Bradley C. ;
Wolchok, Jedd D. ;
Yuan, Jianda ;
Kamat, Ashish ;
Tang, Derek S. Ng ;
Sun, Jingjing ;
Ku, Geoffrey ;
Troncoso, Patricia ;
Logothetis, Christopher J. ;
Allison, James P. ;
Sharma, Padmanee .
CLINICAL CANCER RESEARCH, 2010, 16 (10) :2861-2871
[7]  
Cascone T, 2019, J CLIN ONCOL, V37
[8]   Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial [J].
Eichhorn, Florian ;
Klotz, Laura, V ;
Bischoff, Helge ;
Thomas, Michael ;
Lasitschka, Felix ;
Winter, Hauke ;
Hoffmann, Hans ;
Eichhorn, Martin E. .
BMC CANCER, 2019, 19 (1)
[9]   Neoadjuvant PD-1 Blockade in Resectable Lung Cancer [J].
Forde, P. M. ;
Chaft, J. E. ;
Smith, K. N. ;
Anagnostou, V. ;
Cottrell, T. R. ;
Hellmann, M. D. ;
Zahurak, M. ;
Yang, S. C. ;
Jones, D. R. ;
Broderick, S. ;
Battafarano, R. J. ;
Velez, M. J. ;
Rekhtman, N. ;
Olah, Z. ;
Naidoo, J. ;
Marrone, K. A. ;
Verde, F. ;
Guo, H. ;
Zhang, J. ;
Caushi, J. X. ;
Chan, H. Y. ;
Sidhom, J. -W. ;
Scharpf, R. B. ;
White, J. ;
Gabrielson, E. ;
Wang, H. ;
Rosner, G. L. ;
Rusch, V. ;
Wolchok, J. D. ;
Merghoub, T. ;
Taube, J. M. ;
Velculescu, V. E. ;
Topalian, S. L. ;
Brahmer, J. R. ;
Pardoll, D. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21) :1976-1986
[10]   Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].
Gandhi, L. ;
Rodriguez-Abreu, D. ;
Gadgeel, S. ;
Esteban, E. ;
Felip, E. ;
De Angelis, F. ;
Domine, M. ;
Clingan, P. ;
Hochmair, M. J. ;
Powell, S. F. ;
Cheng, S. Y. -S. ;
Bischoff, H. G. ;
Peled, N. ;
Grossi, F. ;
Jennens, R. R. ;
Reck, M. ;
Hui, R. ;
Garon, E. B. ;
Boyer, M. ;
Rubio-Viqueira, B. ;
Novello, S. ;
Kurata, T. ;
Gray, J. E. ;
Vida, J. ;
Wei, Z. ;
Yang, J. ;
Raftopoulos, H. ;
Pietanza, M. C. ;
Garassino, M. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092